Rafferty Asset Management
AKBA icon

Rafferty Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Rafferty Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-327,110
Closed -$455K – 1135
2026
Q1 		$455K Sell
327,110
-171,513
-34% -$236K ﹤0.01% 897
2025
Q4 		$803K Buy
498,623
+16,754
+3% +$35.1K ﹤0.01% 835
2025
Q3 		$1.32M Buy
481,869
+227,915
+90% +$758K ﹤0.01% 736
2025
Q2 		$924K Buy
253,954
+47,324
+23% +$130K ﹤0.01% 776
2025
Q1 		$397K Buy
206,630
+26,878
+15% +$54.9K ﹤0.01% 911
2024
Q4 		$342K Buy
+179,752
New +$312K ﹤0.01% 998
2022
Q2 		– Sell
-702,647
Closed -$504K – 1127
2022
Q1 		$504K Sell
702,647
-35,428
-5% -$75.8K ﹤0.01% 990
2021
Q4 		$1.67M Buy
738,075
+64,136
+10% +$175K 0.01% 720
2021
Q3 		$1.94M Buy
673,939
+78,993
+13% +$226K 0.01% 643
2021
Q2 		$2.25M Sell
594,946
-328,008
-36% -$1.1M 0.01% 653
2021
Q1 		$3.12M Buy
922,954
+628,925
+214% +$2.27M 0.02% 461
2020
Q4 		$823K Sell
294,029
-220,207
-43% -$643K 0.01% 563
2020
Q3 		$1.29M Buy
514,236
+471,362
+1,099% +$4.14M 0.02% 537
2020
Q2 		$582K Buy
+42,874
New +$444K 0.01% 675
2020
Q1 		– Sell
-57,128
Closed -$361K – 602
2019
Q4 		$361K Sell
57,128
-77,688
-58% -$369K 0.01% 750
2019
Q3 		$528K Sell
134,816
-165,115
-55% -$708K 0.01% 656
2019
Q2 		$1.45M Buy
299,931
+174,540
+139% +$993K 0.03% 493
2019
Q1 		$1.03M Buy
+125,391
New +$860K 0.02% 540

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Rafferty Asset Management's AKBA Position: Q2 2026 in Review

Rafferty Asset Management sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 327,110 shares — an estimated $455K sold.

Rafferty Asset Management first reported a position in AKBA in Q1 2019 and held it in 18 quarters. The position peaked at $3.12M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Rafferty Asset Management reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 327,110 Akebia Therapeutics shares in Q2 2026, an estimated $455K.
  • Rafferty Asset Management first reported a position in Akebia Therapeutics in Q1 2019 and held it in 18 quarters.
  • Rafferty Asset Management's Akebia Therapeutics position peaked at $3.12M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.